Advanced diabetic nephropathy with nephrotic range proteinuria: A pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Tumlin, J A ^a,b   Galphin, C M ^b   Rovin, B H ^c  

^a UNIVERSITY OF TENNESSEE AT CHATTANOOGA   (United States)

^b Southeastern Renal Research Institute   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; PROTEIN; STEROID HORMONE; VASCULOTROPIN; CCL2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOTENSION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; MALE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; URINARY EXCRETION; URINE LEVEL; VASCULOTROPIN URINE LEVEL; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; GEL; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; URINE;

ADRENOCORTICOTROPIC HORMONE; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GELS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884830390     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/489869     Document Type: Article

References (31)

1. De Boer I. H., Rue T. C., Cleary P. A., Lachin J. M., Molitch M. E., Steffes M. W., Sun W., Zinman B., Brunzell J. D., Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Archives of Internal Medicine 2011 171 5 412 420 2-s2.0-79952607968 10.1001/archinternmed.2011.16
2. Bonow R. O., Gheorghiade M., The diabetes epidemic: a national and global crisis. The American Journal of Medicine 2004 116 5 2-s2.0-1542408721 10.1016/j.amjmed.2003.10.014 (Pubitemid 38333036)
3. USRDS, The United States Renal Data System. The American Journal of Kidney Diseases 2003 42 supplement 1 1 230
4. Jaureguia A., Mintz D., Mundela P., Fornonia A., Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and Microalbuminuria. Current Opinion in Nephrology and Hypertension 2009 18 539 545
5. Meyer T. W., Bennett P. H., Nelson R. G., Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999 42 11 1341 1344 2-s2.0-0032710966 10.1007/s001250051447 (Pubitemid 29500971)
6. Ellis E. N., Steffes M. W., Chavers B., Mauer S. M., Observations of glomerular epithelial cell structure in patients with type I diabetes mellitus. Kidney International 1987 32 5 736 741 2-s2.0-0023615540 (Pubitemid 17152405)
7. Berg U. B., Torbjörnsdotter T. B., Jaremko G., Thalme B., Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia 1998 41 9 1047 1056 2-s2.0-0031877454 10.1007/s001250051029 (Pubitemid 28394410)
8. Brown N. J., Nakamura S., Ma L., Nakamura I., Donnert E., Freeman M., Vaughan D. E., Fogo A. B., Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney International 2000 58 3 1219 1227 2-s2.0-0033849916 10.1046/j.1523-1755.2000.00277.x
9. Gross M.-L., El-Shakmak A., Szábó A., Koch A., Kuhlmann A., Münter K., Ritz E., Amann K., ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003 46 6 856 868 2-s2.0-0038235832 10.1007/s00125-003-1106-8 (Pubitemid 36831416)
10. Wolf G., Chen S., Ziyadeh F. N., From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005 54 6 1626 1634 2-s2.0-20044362239 10.2337/diabetes.54.6.1626 (Pubitemid 40770751)
11. Pagtalunan M. E., Miller P. L., Jumping-Eagle S., Nelson R. G., Myers B. D., Rennke H. G., Coplon N. S., Sun L., Meyer T. W., Podocyte loss and progressive glomerular injury in type II diabetes. Journal of Clinical Investigation 1997 99 2 342 348 2-s2.0-0031029379 (Pubitemid 27053474)
12. Wu D. T., Bitzer M., Ju W., Mundel P., Böttinger E. P., TGF- β concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. Journal of the American Society of Nephrology 2005 16 11 3211 3221 2-s2.0-33644877366 10.1681/ASN.2004121055 (Pubitemid 46179327)
13. Pepper M. S., Vassalli J.-D., Orci L., Montesano R., Biphasic effect of transforming growth factor- β 1 on in vitro angiogenesis. Experimental Cell Research 1993 204 2 356 363 2-s2.0-0027176133 10.1006/excr.1993.1043 (Pubitemid 23200200)
14. Steffes M. W., Leffert J. D., Basgen J. M., Epithelial cell foot process width in intact and uninephrectomized diabetic and nondiabetic rats. Laboratory Investigation 1980 43 3 225 230 2-s2.0-0018909568 (Pubitemid 10061702)
15. Steffes M. W., Schmidt D., McCrery R., Basgen J. M., Drummond K., Aebi C., Belmonte M., Gardiner R., Goodyear P., Kramer M., Polychronakos C., Suissz S., Laforte D., Braaten J., Fautht K., Khoury K., Czernichow P., Beaudoin V., Beaufils H., Levy-Marchal C., Gubler M.-C., Passa P., Simon D., Mauer M., Chavers B., Hostetter T., Kim Y., Manske C., Michael A., Saxena K., Sinaiko A., Steffes M., Vernier R., Strand T., Bergenstal R., Sockalosky J., Rich S., Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney International 2001 59 6 2104 2113 2-s2.0-0035008793 10.1046/j.1523-1755. 2001.0590062104.x (Pubitemid 32467602)
16. Dae Ryong Cha D. R. C., Nan Hee Kim N. H. K., Jong Woo Yoon J. W. Y., Sang Kyung Jo S. K. J., Won Yong Cho W. Y. C., Hyoung Kyu Kim H. K. K., Nam Hee Won N. H. W., Role of vascular endothelial growth factor in diabetic nephropathy. Kidney International 2000 77 S104 S112 2-s2.0-0033851522
17. Bailey E., Bottomley M. J., Westwell S., Pringle J. H., Furness P. N., Fechally J., Brenchley P. E. C., Harper S. J., Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. Journal of Clinical Pathology 1999 52 10 735 738 2-s2.0-0032888010 (Pubitemid 29481332)
18. Hohenstein B., Hausknecht B., Boehmer K., Riess R., Brekken R. A., Hugo C. P. M., Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney International 2006 69 9 1654 1661 2-s2.0-33646501496 10.1038/sj.ki.5000294
19. Baelde H. J., Eikmans M., Lappin D. W. P., Doran P. P., Hohenadel D., Brinkkoetter P.-T., Van Der Woude F. J., Waldherr R., Rabelink T. J., De Heer E., Bruijn J. A., Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney International 2007 71 7 637 645 2-s2.0-33846669530 10.1038/sj.ki.5002101 (Pubitemid 46494557)
20. Müller-Deile J., Worthmann K., Saleem M., Tossidou I., Haller H., Schiffer M., The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. The American Journal of Physiology 2009 297 6 F1656 F1667 2-s2.0-71449099347 10.1152/ajprenal.00275.2009
21. Ponticelli C., Passerini P., Salvadori M., Manno C., Viola B. F., Pasquali S., Mandolfo S., Messa P., A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. The American Journal of Kidney Diseases 2006 47 2 233 240 2-s2.0-31044441980 10.1053/j.ajkd.2005.10.016 (Pubitemid 43121326)
22. Gong R., The renaissance of corticotropin therapy in proteinuric nephropathies. Nature Reviews Nephrology 2012 8 2 122 128 2-s2.0-84856509510 10.1038/nrneph.2011.190
23. Lindskog A., Ebefors K., Johansson M. E., Stefánsson B., Granqvist A., Arnadottir M., Berg A.-L., Nyström J., Haraldsson B., Melanocortin 1 receptor agonists reduce proteinuria. Journal of the American Society of Nephrology 2010 21 8 1290 1298 2-s2.0-77955609123 10.1681/ASN.2009101025
24. Amann B., Tinzmann R., Angelkort B., ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003 26 8 2421 2425 2-s2.0-0042524595 10.2337/diacare.26.8.2421 (Pubitemid 36993337)
25. Pergola P. E., Raskin P., Toto R. D., Meyer C. J., Huff J. W., Grossman E. B., Krauth M., Ruiz S., Audhya P., Christ-Schmidt H., Wittes J., Warnock D. G., Bardoxolone methyl and kidney function in CKD with type 2 diabetes. The New England Journal of Medicine 2011 365 4 327 336 2-s2.0-79960855656 10.1056/NEJMoa1105351
26. White K. E., Bilous R. W., Marshall S. M., El Nahas M., Remuzzl G., Piras G., De Cosmo S., Vlberti G., Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002 51 10 3083 3089 2-s2.0-0036789206
27. Zaidi M., Suna L., Robinson B., Tourkovab I., Liub L., Wang Y., ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proceedings of the National Academy of Sciences 2012 107 8782 8787
28. Berg A.-L., Arnadottir M., ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrology Dialysis Transplantation 2004 19 5 1305 1307 2-s2.0-2442505604 10.1093/ndt/gfh110 (Pubitemid 38628157)
29. Farnsworth E. B., Studies on the influence of adrenocorticotropin in acute nephritis in simple nephrosis and in nephrosis with azotemia. Proceedings of the 1st Clinical ACTH Congress 1950 297 317
30. Mallet C., Féraud O., Ouengue-Mbélé G., Gaillard I., Sappay N., Vittet D., Vilgrain I., Differential expression of VEGF receptors in adrenal atrophy induced by dexamethasone: a protective role of ACTH. The American Journal of Physiology 2003 284 1 E156 E167 2-s2.0-0037227772 (Pubitemid 36076234)
31. Shifren J. L., Mesiano S., Taylor R. N., Ferrara N., Jaffe R. B., Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. Journal of Clinical Endocrinology and Metabolism 1998 83 4 1342 1347 2-s2.0-0031732741 10.1210/jc.83.4.1342 (Pubitemid 28496418)